Which has the lower trailing P/E, BTSG or HALO?

HALO has the lower trailing P/E: BTSG trades at 47.48 and HALO at 32.63. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, BTSG or HALO?

Over the past five years, HALO grew revenue faster — BTSG at a 18.92% CAGR versus HALO at 32.18%.

Is BTSG or HALO more profitable?

HALO runs the higher net margin — BTSG at 2.05% versus HALO at 24.86%.

BrightSpring Health Services, Inc. Common Stock (BTSG) vs Halozyme Therapeutics, Inc. (HALO)

A side-by-side comparison of BrightSpring Health Services, Inc. Common Stock and Halozyme Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

BTSG

BrightSpring Health Services, Inc. Common Stock

$12.49B

$63.63HealthcareDelayed quote: Oct 6, 2026, 11:31 AM EDT

HALO

Halozyme Therapeutics, Inc.

$12.96B

$109.30HealthcareDelayed quote: Oct 6, 2026, 11:31 AM EDT

Total return — BTSG vs HALO

growth of $100 · dividends reinvested · last 3y

BTSG +463.6% (+78.0%/yr)HALO +209.0% (+45.7%/yr)BTSG compounded faster over this window

BTSG HALO

BTSG vs HALO: by the numbers

•HALO is the larger company ($12.96B vs $12.49B market cap).
•HALO trades at the lower trailing earnings multiple (32.63 vs 47.48 P/E), one valuation lens rather than an overall verdict.
•HALO converts more revenue to profit (24.86% vs 2.05% net margin).
•HALO grew revenue faster over the past five years (32.18% vs 18.92% CAGR).

Metrics side by side

Valuation

Metric	BTSG	HALO
P/E ratio	47.48	32.63
Forward P/E	35.00	12.99
PEG ratio	0.98	1.42
P/S ratio	0.87	7.79
P/B ratio	6.10	90.32
EV / EBITDA	22.42	14.17
FCF yield	3.22%	6.22%

Profitability

Metric	BTSG	HALO
Gross margin	12.38%	78.18%
Operating margin	3.33%	56.77%
Net margin	2.05%	24.86%
ROE	14.35%	288.13%
ROIC	8.97%	27.42%

Growth (annualized)

Metric	BTSG	HALO
Revenue CAGR (5Y)	18.92%	32.18%
EPS CAGR (5Y)	50.94%	22.68%
FCF CAGR (5Y)	9.24%	40.08%
Total return CAGR (5Y)	N/A	22.18%

Frequently asked

Which has the lower trailing P/E, BTSG or HALO?: HALO has the lower trailing P/E: BTSG trades at 47.48 and HALO at 32.63. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, BTSG or HALO?: Over the past five years, HALO grew revenue faster — BTSG at a 18.92% CAGR versus HALO at 32.18%.
Is BTSG or HALO more profitable?: HALO runs the higher net margin — BTSG at 2.05% versus HALO at 24.86%.

Go deeper

Full BTSG analysis Full HALO analysis Interactive comparison tool

Dig into the metrics

BrightSpring Health Services, Inc. Common Stock P/E ratio Halozyme Therapeutics P/E ratio BrightSpring Health Services, Inc. Common Stock ROE Halozyme Therapeutics ROE BrightSpring Health Services, Inc. Common Stock operating margin Halozyme Therapeutics operating margin BrightSpring Health Services, Inc. Common Stock revenue growth Halozyme Therapeutics revenue growth BrightSpring Health Services, Inc. Common Stock free cash flow Halozyme Therapeutics free cash flow

BrightSpring Health Services, Inc. Common Stock & Halozyme Therapeutics appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest ROIC Stocks Highest Operating Margin Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.